Live Breaking News & Updates on Odette Cancer Center
Stay updated with breaking news from Odette cancer center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study finds melanoma treatment costs have increased, but so has survival healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Two tiers aren't solution to healthcare | Caledon Citizen caledoncitizen.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from caledoncitizen.com Daily Mail and Mail on Sunday newspapers.
A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment. ....
Self-reported signs of distress and an increasing total Edmonton Symptom Assessment System score within 180 days of cancer diagnosis appeared associated with higher odds of nonfatal, self-inflicted injury, study results showed.The findings, published in JAMA Oncology, highlighted the need to monitor patient-reported outcomes and use them to direct management, according to researchers. ....
E-Mail IMAGE: Kenneth Grossmann, MD, PhD, of Huntsman Cancer Institute, led the SWOG S1404 clinical trial, which found that patients with high-risk melanoma who had pembrolizumab after their surgery had a longer. view more Credit: Huntsman Cancer Institute PORTLAND, OR - Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021. Researchers also measured overall survival and found no statistically significant difference in overall survival rates between the two groups of patients three and one-half years after the last patient enrolled to the trial. They did find, however, that patients taking pembrolizumab had fewer serious side effects than those treated with e ....